Humacyte Announces Appointment of Three Surgical and Cardiovascular Opinion Leaders to Advisory Positions
DURHAM, NC, December 31, 2021 (GLOBE NEWSWIRE) – Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues on a commercial scale, announced today the appointment of Surgical Key Opinion Leaders (KOL) Alan P. Kypson, MD, FACS; Luigi Pascarella, MD, FACS; and Todd E. Rasmussen, MD, FACS, (Col, ret. USAF MC), to new advisory positions. In these roles, KOLs will bring their expertise and support to guide human acellular vessel training and clinical advancement efforts.MT (HAV) and help identify opportunities to advance the complex tissue constructs pipeline and platform at an early stage of the company.
Humacyte HAVs are ready-to-use replacement vessels currently being evaluated in advanced clinical trials in the areas of vascular trauma, arteriovenous access for hemodialysis, and peripheral arterial disease (PAD). HAVs are also being used to treat patients with severe PAD under investigator-sponsored IND No. 27864, filed with the United States Food and Drug Administration (FDA) by Dr. Rasmussen, at the Mayo Clinic in Rochester, Minn.
“Dr. Kypson, Pascarella and Rasmussen are luminaries in the fields of cardiac, vascular and traumatic surgery, and we have had the pleasure of working with them in a variety of capacities as we developed HAV,” said Laura Niklason, MD , Ph.D., Founder, President and CEO of Humacyte. “We are delighted to now formalize their roles as foundational advisors to our clinical and surgical teams, as we prepare for our next phase of growth, the anticipated commercialization of HAV in its initial vascular indications and the expected expansion of applications for our off-standard regenerative medicine technology.
Dr Kypson is a cardiothoracic surgeon at Rex Hospital, University of North Carolina, Raleigh, North Carolina. Previously, he was Professor of Surgery at the Brody School of Medicine and Head of the Division of Cardiothoracic Surgery at the East Carolina Heart Institute. Dr Kypson has led the large animal preclinical development of Humacyte vessels in coronary artery bypass grafting for over a decade and has authored over 100 publications, primarily in the area of coronary artery bypass grafting. cardiovascular surgery.
Dr Pascarella is a vascular surgeon and associate professor and vice president of surgery at the University of North Carolina School of Medicine in Chapel Hill, North Carolina. Dr Pascarella received a Fellowship in Vascular Biology in the Department of Bioengineering at the University of California at San Diego and his postgraduate surgical training at Duke University. He has performed preclinical studies on several animal models of vascular disease, including studies with HAV. Dr Pascarella is the author of numerous publications in peer-reviewed medical journals, with an emphasis on vascular surgery, aortic disease and medical education.
Dr Rasmussen is Professor and Vice President of Education in the Department of Surgery and Senior Associate Consultant in the Division of Vascular and Endovascular Surgery at the Mayo Clinic. Prior to joining Mayo, Dr. Rasmussen served nearly three decades in the US Air Force, retiring as Colonel in 2021. While in the Air Force, Dr. Rasmussen completed several periods of service with the Air Force. Middle East and launched a research and innovation program on the control of vascular lesions and hemorrhages. Dr. Rasmussen’s research has resulted in more than 300 publications, primarily in the areas of vascular injury and shock, including two textbooks, the Manual of patient care in vascular disease and Rich’s vascular trauma. He is also the co-inventor of the REBOA Rescue Device, a minimally invasive technique for managing severe bleeding and shock.
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve patient lives and transform the practice of medicine. The Company develops and manufactures acellular tissue to treat a wide variety of illnesses, injuries and chronic illnesses. The initial opportunity for Humacyte, a human acellular vessel (HAV) portfolio, is currently in advanced clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis and peripheral arterial disease. Preclinical development is also underway in coronary artery bypass grafts, pediatric cardiac surgery, the treatment of type 1 diabetes, and multiple new cellular and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Advanced Regenerative Therapy (RMAT) Accelerated Review Designation and received Priority Designation for the Treatment of Vascular Trauma by the US Secretary of Defense. For more information, visit www.Humacyte.com.
Humacyte Investor Contact:
Humacyte media contact: